M Donaghy1, S M Sisodiya, R Kennett, B McDonald, N Haites, C Bell. 1. Department of Clinical Neurology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK. Joanne.Wilkinson@clineuro.ox.ac.uk
Abstract
OBJECTIVE: To report a novel hereditary motor and sensory neuropathy (HMSN) phenotype, with partial steroid responsiveness, caused by a novel dominant mutation in the myelin protein zero (MPZ) gene. Most MPZ mutations lead to the HMSN type I phenotype, with recent reports of Déjérine-Sottas, congenital hypomyelination, and HMSN II also ascribed to MPZ mutations. Differing phenotypes may reflect the effect of particular mutations on MPZ structure and adhesivity. METHODS: Clinical, neurophysiological, neuropathological, and molecular genetic analysis of a family presenting with an unusual hereditary neuropathy. RESULTS: Progressive disabling weakness, with positive sensory phenomena and areflexia, occurred in the proband with raised CSF protein and initial steroid responsiveness. Nerve biopsy in a less severely affected sibling disclosed a demyelinating process with disruption of compacted myelin. The younger generation were so far less severely affected, becoming symptomatic only after 30 years. All affected family members were heterozygous for a novel MPZ mutation (Ile99Thr), in a conserved residue. CONCLUSIONS: This broadens the range of familial neuropathy associated with MPZ mutations to include steroid responsive neuropathy, initially diagnosed as chronic inflammatory demyelinating polyneuropathy.
OBJECTIVE: To report a novel hereditary motor and sensory neuropathy (HMSN) phenotype, with partial steroid responsiveness, caused by a novel dominant mutation in the myelin protein zero (MPZ) gene. Most MPZ mutations lead to the HMSN type I phenotype, with recent reports of Déjérine-Sottas, congenital hypomyelination, and HMSN II also ascribed to MPZ mutations. Differing phenotypes may reflect the effect of particular mutations on MPZ structure and adhesivity. METHODS: Clinical, neurophysiological, neuropathological, and molecular genetic analysis of a family presenting with an unusual hereditary neuropathy. RESULTS: Progressive disabling weakness, with positive sensory phenomena and areflexia, occurred in the proband with raised CSF protein and initial steroid responsiveness. Nerve biopsy in a less severely affected sibling disclosed a demyelinating process with disruption of compacted myelin. The younger generation were so far less severely affected, becoming symptomatic only after 30 years. All affected family members were heterozygous for a novel MPZ mutation (Ile99Thr), in a conserved residue. CONCLUSIONS: This broadens the range of familial neuropathy associated with MPZ mutations to include steroid responsive neuropathy, initially diagnosed as chronic inflammatory demyelinating polyneuropathy.
Authors: S Bort; E Nelis; V Timmerman; T Sevilla; A Cruz-Martínez; F Martínez; J M Millán; J Arpa; J J Vílchez; F Prieto; C Van Broeckhoven; F Palau Journal: Hum Genet Date: 1997-06 Impact factor: 4.132
Authors: M E Shy; E Arroyo; J Sladky; D Menichella; H Jiang; W Xu; J Kamholz; S S Scherer Journal: J Neuropathol Exp Neurol Date: 1997-07 Impact factor: 3.685
Authors: J Tyson; D Ellis; U Fairbrother; R H King; F Muntoni; J Jacobs; S Malcolm; A E Harding; P K Thomas Journal: Brain Date: 1997-01 Impact factor: 13.501
Authors: D H Kilfoyle; P J Dyck; Y Wu; W J Litchy; D M Klein; P J B Dyck; N Kumar; J M Cunningham; C J Klein Journal: J Neurol Neurosurg Psychiatry Date: 2006-08 Impact factor: 10.154
Authors: C J Klein; P J B Dyck; S M Friedenberg; T M Burns; A J Windebank; P J Dyck Journal: J Neurol Neurosurg Psychiatry Date: 2002-07 Impact factor: 10.154
Authors: Oranee Sanmaneechai; Shawna Feely; Steven S Scherer; David N Herrmann; Joshua Burns; Francesco Muntoni; Jun Li; Carly E Siskind; John W Day; Matilde Laura; Charlotte J Sumner; Thomas E Lloyd; Sindhu Ramchandren; Rosemary R Shy; Tiffany Grider; Chelsea Bacon; Richard S Finkel; Sabrina W Yum; Isabella Moroni; Giuseppe Piscosquito; Davide Pareyson; Mary M Reilly; Michael E Shy Journal: Brain Date: 2015-08-25 Impact factor: 13.501